FDA Advisory Committee recommends approval of Eli Lilly donanemab
Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation jcm9144@gmail.com
SPECIAL REPORT 24.06
US FDA Advisory Committee recommends approval of Eli Lilly donanemab
On June 10, 2024, the US FDA Peripheral and Central Nervous System Drugs Advisory Committee panel recommended approval of Eli Lilly’s donanemab for the treatment of early-stage Alzheimer’s disease.
The panel voted 11-0 that donanemab’s benefit outweighs its risks. It also voted 11-0 that the data presented by Eli Lilly showed that the drug was effective in the early stage of the disease.
Donanemab showed a 37% lower risk of progression of a clinical measure of dementia in patients treated over 76 weeks.
One of the members of the panel said if donanemab is approved, patients should carry a medical information card to indicate that they are being treated with the drug in order to inform doctors and caregivers of the risk if they also receive a blood thinner.
The panel also discussed in some length the fact that donanemab was more effective in patients with low tau levels and less advanced disease and was wondering if the drug should be restricted to patients with low-to-medium tau levels in their cerebrospinal fluid and how to extrapolate to patients with no tau levels, a group which had been excluded from the study.
The FDA usually follows the recommendation of its advisory panel. The final decision on donanemab approval by the FDA has already been delayed twice and is now expected by the end of the year. It is not known if a similar dossier has been filed by Eli Lilly in Europe or in Japan.
Paris, June 11, 2024.
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.
Last News
- Note de réflexion de fin d’année
- EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease
- Le déclassement de la France
Events
News archives
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012